Literature DB >> 22146321

Multiple sclerosis- diagnosis, management and prognosis.

Benjamin K-T Tsang1, Richard Macdonell.   

Abstract

BACKGROUND: Multiple sclerosis is the most common chronic disabling disease of the central nervous system in young adults.
OBJECTIVE: This article summarises the diagnosis, management and prognosis of multiple sclerosis. DISCUSSION: Multiple sclerosis usually starts with an acute episode of neurological disturbance, termed a 'clinically isolated syndrome', followed by an illness phase punctuated by relapses and remissions which may transition after 10 years to a phase of progressive accumulation of disability without relapses. Fifteen to 20% of patients will have a progressive course from the onset. There is significant interpatient variability in prognosis. The main diagnostic criteria are clinical, supported by investigations including magnetic resonance imaging and lumbar puncture and evoked potentials. First line disease modifying agents for relapsing remitting multiple sclerosis include interferon-ß and glatiramer. First line treatment for relapses is usually intravenous methylprednisolone for 3 days. Troublesome symptoms may include spasticity, parasthesias, tremor, erectile dysfunction, depression and anxiety, fatigue and pain. After excluding differential diagnoses, symptomatic management includes pharmacological agents, allied health consultation and continence strategies. Although pregnancy reduces disease activity, there is a higher risk of relapse in the postpartum period.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22146321

Source DB:  PubMed          Journal:  Aust Fam Physician        ISSN: 0300-8495


  18 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

2.  Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease.

Authors:  B Rodríguez-Sánchez; S Daugbjerg; L M Peña-Longobardo; J Oliva-Moreno; I Aranda-Reneo; A Cicchetti; J López-Bastida
Journal:  Eur J Health Econ       Date:  2022-05-20

Review 3.  Toxic Air Pollutants and Their Effect on Multiple Sclerosis: A Review Study.

Authors:  Mohammad Javad Mohammadi; Kourosh Zarea; Nasser Hatamzadeh; Arash Salahshouri; Asaad Sharhani
Journal:  Front Public Health       Date:  2022-07-06

Review 4.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

5.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01

Review 6.  Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.

Authors:  Stacey Murray; Andrew Woo
Journal:  Ther Adv Neurol Disord       Date:  2015-12-07       Impact factor: 6.570

7.  Effect of a self-management and follow-up program on self-efficacy in patients with multiple sclerosis: a randomized clinical trial.

Authors:  Masomeh Hemmati Maslakpak; Zahra Raiesi
Journal:  Nurs Midwifery Stud       Date:  2014-12-29

8.  Tremor in Multiple System Atrophy - a review.

Authors:  Christine Kaindlstorfer; Roberta Granata; Gregor Karl Wenning
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-09-03

9.  Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.

Authors:  Alireza Olyaeemanesh; Mahbobeh Rahmani; Reza Goudarzi; Abulghasem Rahimdel
Journal:  Med J Islam Repub Iran       Date:  2016-02-23

10.  Identification of key genes and microRNAs for multiple sclerosis using bioinformatics analysis.

Authors:  Zhong-Bo Xu; Xin Feng; Wei-Na Zhu; Ming-Liang Qiu
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.